TLR7 and influenza: They found that the vaccination with a Toll-like receptor 7 (TLR7) agonist nanoparticle adjuvanted influenza subunit vaccine was effective against different influenza strains and in combination with a SARS-CoV-2 subunit vaccine enhanced the immune response against variants of both viruses [20].